Long before GLP-1 drugs like Ozempic, Wegovy, and Zepbound became the latest weight-loss craze, there was Olestra.
For those too young to remember, Olestra was supposed to be revolutionary. Developed by Procter & Gamble, Olestra was a fat substitute that promised all the taste of fat without the calories. The human body could not digest it, meaning it would pass through the digestive system without being absorbed. In theory, you could eat potato chips and other snack foods without consuming the fat that made them so unhealthy.
It sounded too good to be true. As it turned out, it was.
After years of development and regulatory review, Olestra received approval from the U.S. Food and Drug Administration in 1996. Soon after, fat-free WOW potato chips appeared on store shelves. Consumers rushed to try them. Dieters were excited. Food companies believed they had found the future.
Then reality intervened.
Because Olestra was not absorbed by the body, it could also produce some rather unpleasant side effects. Consumers reported abdominal cramping, diarrhea, and the infamous “anal leakage” warning that became the butt of countless jokes (pun intended). The product’s reputation never recovered. It didn’t matter how many calories people saved if they were worried about what might happen during their commute home.
Years later, another fat-loss product called Alli attempted a different approach by blocking fat absorption rather than replacing fat entirely. It came with its own warnings about oily discharge and urgent bathroom visits if users consumed too much dietary fat. Apparently, science had found multiple ways to reduce fat absorption, and none of them were particularly dignified.
Looking back, Olestra serves as a reminder that every generation seems to search for a shortcut to weight loss. Sometimes those shortcuts work, and sometimes they create new problems nobody anticipated. Olestra promised guilt-free snacking. Instead, it became one of the most memorable product failures in food history.
